Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 15 full-time employees. The firm is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The firm`s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The firm is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
Website: arcabio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.96 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.7% (LTM)

Entry Point: Share price is 1 723.0% higher than minimum and 0.2% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: ABIO
Share price, USD:  (0.0%)28.8
year average price 28.80  


year start price 28.80 2025-11-13

max close price 28.80 2025-11-13

min close price 28.80 2025-11-13

current price 28.80 2026-11-12
Common stocks: 14 410 100

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 415
Net Debt ($m): -58
EV (Enterprise Value): 357
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-08-26globenewswire.com

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

2024-08-23globenewswire.com

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

2024-08-16globenewswire.com

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

2024-05-14InvestorPlace

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

2024-04-03InvestorPlace

Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

2024-04-03Invezz

Arca Biopharma stock ($ABIO) soars on merger news
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2025-09-30 2025-06-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654
fillingDate 2025-11-12 2025-08-11 2024-08-01 2024-04-25 2023-10-18 2023-07-21 2023-04-24 2022-10-28
acceptedDate 2025-11-12 16:02:52 2025-08-11 16:01:07 2024-08-01 16:05:23 2024-04-25 16:15:26 2024-02-01 16:15:34 2023-10-18 16:15:25 2023-07-21 16:16:06 2023-04-24 16:16:04 2023-02-24 16:16:45 2022-10-28 16:06:07 2022-03-14 16:06:34 2021-03-18 16:06:08 2020-02-18 16:16:43
calendarYear 2025 2025 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 12 000 19 000 111 000 30 000 0 0 114 000 0 91 000 93 000 89 000
grossProfit 0 0 -12 000 -19 000 -111 000 -30 000 0 0 -114 000 0 -91 000 -93 000 -89 000
grossProfitRatio 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 29M 24M 130 000 165 000 1M 322 000 254 000 390 000 5M 1M 14M 5M 2M
generalAndAdministrativeExpenses 5M 4M 3M 2M 6M 2M 2M 1M 6M 2M 6M 5M 4M
sellingAndMarketingExpenses 0 0 -382 000 2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 4M 3M 2M 6M 2M 2M 1M 6M 2M 6M 5M 4M
otherExpenses 0 0 0 0 -111 000 0 0 0 0 0 0 0 0
operatingExpenses 34M 28M 3M 2M 7M 2M 2M 2M 11M 3M 19M 10M 6M
costAndExpenses 0 0 3M 2M 7M 2M 2M 2M 11M 3M 19M 10M 6M
interestIncome 4M 4M 444 000 473 000 2M 513 000 493 000 450 000 675 000 222 000 13 000 28 000 172 000
interestExpense 0 0 0 0 0 0 0 -450 000 675 000 222 000 0 9000 7000
depreciationAndAmortization 20 000 0 12 000 19 000 15 000 30 000 29 000 29 000 114 000 469 000 91 000 93 000 18 000
ebitda -30M -28M -3M -2M -7M -2M -2M -2M -10M -2M -19M -10M -6M
ebitdaratio 0 0 0 0 0 0 0 0
operatingIncome -34M -28M -3M -2M -7M -2M -2M -2M -10M -3M -19M -10M -6M
operatingIncomeRatio 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 4M 4M 74 000 473 000 2M 513 000 493 000 450 000 -85 000 219 000 13 000 19 000 165 000
incomeBeforeTax -30M -25M -3M -2M -5M -1M -1M -1M -10M -2M -19M -10M -6M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 -24 812 0 -30 000 -522 000 -450 000 -670 000 -219 000 -91 000 -9000 -167 000
netIncome -30M -25M -3M -2M -5M -1M -958 000 -896 000 -10M -2M -19M -10M -5M
netIncomeRatio 0 0 0 0 0 0 0 0
eps -45.46 -38.26 -0.18 -0.14 -0.37 -0.099 -0.067 -0.062 -0.69 -0.15 -1.39 -2.07 -4.15
epsdiluted -45.46 -38.26 -0.18 -0.14 -0.099 -0.067 -0.062 -0.15
weightedAverageShsOut 44 067 42 095 15M 15M 14M 14M 14M 14M 14M 14M 14M 5M 1M
weightedAverageShsOutDil 44 067 42 095 15M 15M 14M 14M 14M 14M 14M 14M 14M 5M 1M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2024-02-01 2023-02-24 2022-03-14 2021-03-18 2020-02-18
fiscalYear 2023 2022 2021 2020 2019
netInterestIncome 2M 0 13 000 19 000 165 000
ebit -7M -10M -19M -10M -6M
nonOperatingIncomeExcludingInterest 0 0 0 -28 000 -172 000
netIncomeFromContinuingOperations -5M -9M -19M -10M -5M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -5M -9M -19M -10M -5M
epsDiluted -0.37 -0.69 -1.39 -2.07 -4.15

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2025-09-30 2025-06-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654
fillingDate 2025-11-12 2025-08-11 2024-08-01 2024-04-25 2023-10-18 2023-07-21 2023-04-24 2022-10-28
acceptedDate 2025-11-12 16:02:52 2025-08-11 16:01:07 2024-08-01 16:05:23 2024-04-25 16:15:26 2024-02-01 16:15:34 2023-10-18 16:15:25 2023-07-21 16:16:06 2023-04-24 16:16:04 2023-02-24 16:16:45 2022-10-28 16:06:07 2022-03-14 16:06:34 2021-03-18 16:06:08 2020-02-18 16:16:43
calendarYear 2025 2025 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY FY
cashAndCashEquivalents 91M 65M 33M 36M 37M 38M 40M 41M 42M 44M 53M 49M 8M
shortTermInvestments 258M 263M 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 349M 328M 33M 36M 37M 38M 40M 41M 42M 44M 53M 49M 8M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 6M 4M 537 000 767 000 161 000 405 000 599 000 852 000 254 000 611 000 1M 897 000 117 000
totalCurrentAssets 355M 332M 34M 37M 38M 39M 41M 42M 43M 45M 54M 50M 8M
propertyPlantEquipmentNet 2M 2M 12 000 24 000 257 000 280 000 310 000 339 000 368 000 397 000 485 000 449 000 32 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 152M 23M 12 000 12 000 12 000 12 000 18 000 18 000 18 000 18 000 18 000 12 000 24 000
totalNonCurrentAssets 154M 25M 24 000 36 000 269 000 292 000 328 000 357 000 386 000 415 000 503 000 461 000 56 000
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 509M 357M 34M 37M 38M 39M 41M 42M 43M 45M 55M 50M 9M
accountPayables 2M 5M 571 000 529 000 362 000 322 000 241 000 366 000 334 000 593 000 1M 2M 418 000
shortTermDebt 419 000 660 000 0 0 0 77 000 0 0 103 000 0 100 000 41 000 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 -529 000 0 -77 000 0 0 -103 000 0 -100 000 0 -25 000
otherCurrentLiabilities 18M 7M 700 000 1M 100 000 670 000 1M 900 000 173 000 1M 925 000 774 000 154 000
totalCurrentLiabilities 21M 12M 1M 2M 637 000 992 000 2M 1M 1M 2M 3M 3M 926 000
longTermDebt 1M 2M 0 0 204 000 224 000 243 000 262 000 280 000 301 000 383 000 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 -204 000 0 0 0 -280 000 -292 000 -383 000 0 0
totalNonCurrentLiabilities 1M 2M 0 0 204 000 224 000 243 000 262 000 280 000 301 000 383 000 409 000 0
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 204 000 224 000 243 000 262 000 280 000 301 000 383 000 409 000 0
totalLiabilities 22M 14M 1M 2M 841 000 1M 2M 2M 1M 2M 4M 4M 926 000
preferredStock 3M 3M 0 0 0 0 0 0 0 0 0 0 0
commonStock 10M 3M 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 10000 2000
retainedEarnings -160M -129M -193M -191M -189M -188M -186M -185M -183M -182M -173M -154M -144M
accumulatedOtherComprehensiveIncomeLoss 185 000 -27 000 0 0 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 636M 470M 226M 226M 226M 225M 225M 225M
totalStockholdersEquity 487M 344M 33M 35M 37M 38M 39M 41M 42M 43M 51M 47M 8M
totalEquity 487M 344M 33M 35M 37M 38M 39M 41M 42M 43M 51M 47M 8M
totalLiabilitiesAndStockholdersEquity 509M 357M 34M 37M 39M 41M 42M 45M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 509M 357M 34M 37M 38M 39M 41M 42M 43M 45M 55M 50M 9M
totalInvestments 0 263M 0 0 0 0 0 0 0 0 0 0 0
totalDebt 2M 2M 24 000 48 000 204 000 224 000 243 000 262 000 280 000 301 000 383 000 409 000 25 000
netDebt -89M -63M -33M -36M -37M -38M -40M -41M -42M -44M -53M -49M -8M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2024-02-01 2023-02-24 2022-03-14 2021-03-18 2020-02-18
fiscalYear 2023 2022 2021 2020 2019
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 362 000 334 000 1M 2M 418 000
otherPayables 0 0 0 0 0
accruedExpenses 175 000 625 000 1M 911 000 379 000
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 204 000 280 000 383 000 409 000 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 226M 225M 225M 201M 152M
otherTotalStockholdersEquity 226M 225M 225M 201M 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2025-09-30 2025-06-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO ABIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654 907 654
fillingDate 2025-11-12 2025-08-11 2024-08-01 2024-04-25 2023-10-18 2023-07-21 2023-04-24 2022-10-28
acceptedDate 2025-11-12 16:02:52 2025-08-11 16:01:07 2024-08-01 16:05:23 2024-04-25 16:15:26 2024-02-01 16:15:34 2023-10-18 16:15:25 2023-07-21 16:16:06 2023-04-24 16:16:04 2023-02-24 16:16:45 2022-10-28 16:06:07 2022-03-14 16:06:34 2021-03-18 16:06:08 2020-02-18 16:16:43
calendarYear 2025 2025 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY FY
netIncome -30M -25M -3M -2M -5M -1M -1M -1M -10M -2M -19M -10M -5M
depreciationAndAmortization 20 000 19 000 12 000 19 000 111 000 30 000 29 000 29 000 114 000 28 000 91 000 93 000 89 000
deferredIncomeTax 0 0 0 0 0 -214 000 0 0 0 0 -1M 872 000 -141 000
stockBasedCompensation 10M 5M 112 000 114 000 686 000 154 000 187 000 204 000 556 000 97 000 497 000 43 000 151 000
changeInWorkingCapital 0 0 -80 000 348 000 -472 000 -429 000 570 000 -482 000 -2M -293 000 -28 000 2M 441 000
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -2M 1M 42 000 167 000 28 000 81 000 -125 000 32 000 -783 000 -517 000 -411 000 1M 188 000
otherWorkingCapital 0 0 -289 000 348 000 -500 000 -510 000 695 000 -514 000 -878 000 224 000 383 000 776 000 253 000
otherNonCashItems -2M -4M 136 000 152 000 0 214 000 0 0 5000 3000 1M -872 000 141 000
netCashProvidedByOperatingActivities -22M -23M -3M -2M -5M -2M -694 000 -2M -11M -2M -19M -8M -5M
investmentsInPropertyPlantAndEquipment -99 000 -34 000 0 0 0 0 0 0 -2000 0 -43 000 -19 000 -4000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -268M -108M 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 145M 113M 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 -2000 0
netCashUsedForInvestingActivites -122M 5M 0 0 0 0 -2000 0
debtRepayment 0 0 0 0 0 0 0 0
commonStockIssued 0 109 000 14 000 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 170M 109 000 14 000 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 170M 109 000 14 000 0 0 0 0 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 26M -18M -3M -2M -5M -2M -694 000 -2M -11M -2M 4M 41M 2M
cashAtEndOfPeriod 91M 65M 33M 36M 37M 38M 40M 41M 42M 44M 53M 49M 8M
cashAtBeginningOfPeriod 65M 84M 36M 37M 42M 40M 41M 42M 53M 46M 49M 8M 7M
operatingCashFlow -22M -23M -3M -2M -5M -2M -694 000 -2M -11M -2M -19M -8M -5M
capitalExpenditure -99 000 -34 000 0 0 0 0 0 0 -2000 0 -43 000 -19 000 -4000
freeCashFlow -22M -23M -3M -2M -5M -2M -694 000 -2M -11M -2M -19M -8M -5M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2024-02-01 2023-02-24 2022-03-14 2021-03-18 2020-02-18
fiscalYear 2023 2022 2021 2020 2019
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 0 -2000 -43 000 -19 000 -4000
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 24M 51M 7M
netCommonStockIssuance 0 0 24M 51M 7M
commonStockIssuance 0 0 24M 51M 7M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 -977 000 -2M -721 000
netCashProvidedByFinancingActivities 0 0 23M 48M 7M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2024-08-01 20:15 ET
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
2024-04-25 20:15 ET
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-03 11:30 ET
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
2024-02-01 21:35 ET
ARCA biopharma Announces 2023 Financial Results
2023-10-18 20:25 ET
ARCA biopharma Announces Third Quarter 2023 Financial Results
2023-07-21 20:25 ET
ARCA biopharma Announces Second Quarter 2023 Financial Results
2023-04-24 20:25 ET
ARCA biopharma Announces First Quarter 2023 Financial Results
2023-02-24 21:20 ET
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
2022-12-19 21:05 ET
James Flynn Joins ARCA biopharma Board of Directors
2022-10-28 20:15 ET
ARCA biopharma Announces Third Quarter 2022 Financial Results
2022-08-02 20:15 ET
ARCA biopharma Announces Second Quarter 2022 Financial Results
2022-06-21 20:05 ET
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
2022-05-05 20:15 ET
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
2022-05-02 20:15 ET
ARCA biopharma Announces First Quarter 2022 Financial Results
2022-04-18 20:30 ET
ARCA biopharma Establishes Special Committee of the Board of Directors
2022-03-31 20:15 ET
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
2022-03-14 20:15 ET
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
2022-01-04 13:30 ET
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
2021-12-02 13:30 ET
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
2021-11-09 21:15 ET
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
2021-11-02 20:15 ET
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
2021-10-28 20:30 ET
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
2021-09-16 12:30 ET
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
2021-08-16 12:05 ET
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
2021-08-09 12:00 ET
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
2021-08-04 20:15 ET
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
2021-07-28 12:00 ET
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
2021-07-13 12:00 ET
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
2021-07-09 12:00 ET
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
2021-07-07 12:00 ET
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
2021-05-11 20:15 ET
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-05 20:05 ET
Christopher Graybill Joins ARCA as Vice President, Clinical Development
2021-05-03 20:30 ET
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
2021-03-18 20:30 ET
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
2020-12-15 13:30 ET
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
2020-12-09 22:40 ET
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
2020-11-23 13:30 ET
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
2020-11-02 13:30 ET
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
2020-10-07 12:30 ET
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
2020-10-05 20:30 ET
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality
2020-09-21 12:00 ET
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
2020-08-12 12:00 ET
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19
2020-08-05 20:15 ET
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-07 12:30 ET
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
2020-06-03 13:55 ET
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
2020-06-01 12:20 ET
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
2020-05-28 12:00 ET
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
2020-05-07 12:30 ET
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
2020-05-06 20:30 ET
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
2020-02-18 21:30 ET
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
2019-11-06 21:10 ET
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
2019-09-12 12:30 ET
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
2019-09-11 12:30 ET
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

SEC forms

Show financial reports only

SEC form 10
2026-11-09 00:00 ET
ARCA biopharma reported for 2026 q3
SEC form 8
2026-10-26 12:00 ET
ARCA biopharma published news for 2026 q3
SEC form 8
2026-10-26 12:00 ET
ARCA biopharma published news for 2026 q3
SEC form 8
2026-10-26 12:00 ET
ARCA biopharma published news for 2026 q3
SEC form 10
2026-08-10 20:06 ET
ARCA biopharma reported for 2026 q2
SEC form 8
2026-08-10 11:00 ET
ARCA biopharma reported for 2026 q2
SEC form 8
2026-08-10 11:00 ET
ARCA biopharma published news for 2026 q2
SEC form 8
2026-06-01 20:01 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-06-01 20:01 ET
ARCA biopharma published news for 2026 q1
SEC form 10
2026-05-13 20:01 ET
ARCA biopharma reported for 2026 q1
SEC form 8
2026-04-30 20:17 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-30 20:17 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-30 20:17 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-30 20:17 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-27 12:00 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-27 12:00 ET
ARCA biopharma published news for 2026 q1
SEC form 8
2026-04-27 12:00 ET
ARCA biopharma published news for 2026 q1
SEC form 10
2026-03-12 20:03 ET
ARCA biopharma reported for 2025 q4
SEC form 10
2025-11-12 16:02 ET
ARCA biopharma reported for 2025 q3
SEC form 10
2025-08-11 20:01 ET
ARCA biopharma reported for 2025 q2
SEC form 10
2025-05-14 20:02 ET
ARCA biopharma reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
ARCA biopharma reported for 2025 q1
SEC form 10
2025-03-06 21:02 ET
ARCA biopharma published news for 2024 q4
SEC form 10
2025-03-06 00:00 ET
ARCA biopharma published news for 2024 q4
SEC form 10
2024-11-13 16:01 ET
ARCA biopharma reported for 2024 q3
SEC form 10
2024-11-13 00:00 ET
ARCA biopharma reported for 2024 q3
SEC form 8
2024-08-01 16:25 ET
ARCA biopharma published news for 2024 q2
SEC form 8
2024-08-01 16:25 ET
ARCA biopharma published news for 2024 q2
SEC form 10
2024-08-01 16:05 ET
ARCA biopharma reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
ARCA biopharma reported for 2024 q2
SEC form 8
2024-04-25 16:25 ET
ARCA biopharma published news for 2024 q1
SEC form 8
2024-04-25 16:25 ET
ARCA biopharma published news for 2024 q1
SEC form 10
2024-04-25 16:15 ET
ARCA biopharma reported for 2024 q1
SEC form 10
2024-04-25 00:00 ET
ARCA biopharma reported for 2024 q1
SEC form 10
2024-02-01 00:00 ET
ARCA biopharma reported for 2023 q4
SEC form 8
2024-02-01 00:00 ET
ARCA biopharma published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
ARCA biopharma published news for 2023 q4
SEC form 10
2023-10-18 16:15 ET
ARCA biopharma reported for 2023 q3
SEC form 10
2023-10-18 00:00 ET
ARCA biopharma reported for 2023 q3
SEC form 8
2023-10-18 00:00 ET
ARCA biopharma published news for 2023 q3
SEC form 10
2023-07-21 00:00 ET
ARCA biopharma reported for 2023 q2
SEC form 8
2023-07-21 00:00 ET
ARCA biopharma reported for 2023 q2
SEC form 8
2023-04-24 00:00 ET
ARCA biopharma reported for 2023 q1
SEC form 10
2023-04-24 00:00 ET
ARCA biopharma reported for 2023 q1
SEC form 8
2023-02-24 00:00 ET
ARCA biopharma reported for 2022 q4
SEC form 10
2023-02-24 00:00 ET
ARCA biopharma reported for 2022 q4
SEC form 8
2022-10-28 00:00 ET
ARCA biopharma reported for 2022 q3
SEC form 10
2022-10-28 00:00 ET
ARCA biopharma reported for 2022 q3
SEC form 8
2022-08-02 00:00 ET
ARCA biopharma reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
ARCA biopharma reported for 2022 q2
SEC form 8
2022-05-02 00:00 ET
ARCA biopharma reported for 2022 q1
SEC form 10
2022-05-02 00:00 ET
ARCA biopharma reported for 2022 q1
SEC form 8
2022-03-14 00:00 ET
ARCA biopharma published news for 2021 q4
SEC form 10
2022-03-14 00:00 ET
ARCA biopharma published news for 2021 q4
SEC form 8
2021-11-02 00:00 ET
ARCA biopharma published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
ARCA biopharma published news for 2021 q3
SEC form 8
2021-08-04 00:00 ET
ARCA biopharma published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
ARCA biopharma published news for 2021 q2
SEC form 10
2021-05-11 00:00 ET
ARCA biopharma published news for 2021 q1